Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
Shaun O’Hagan,1,2 Niamh Galway,3 Michael D Shields,3,4 Peter Mallett,1,4 Helen E Groves1,2 1Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland; 2Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, Northern Irelan...
Main Authors: | O'Hagan S, Galway N, Shields MD, Mallett P, Groves HE |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-09-01
|
Series: | Drug, Healthcare and Patient Safety |
Subjects: | |
Online Access: | https://www.dovepress.com/review-of-the-safety-efficacy-and-tolerability-of-palivizumab-in-the-p-peer-reviewed-fulltext-article-DHPS |
Similar Items
-
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01) -
Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01) -
Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
by: Gwenaelle Mulot, et al.
Published: (2022-07-01) -
Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
by: Rutger M. Schepp, et al.
Published: (2023-12-01) -
Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)